These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11588850)

  • 1. Molecular epidemiology of hormone-metabolic loci in prostate cancer.
    Makridakis NM; Reichardt JK
    Epidemiol Rev; 2001; 23(1):24-9. PubMed ID: 11588850
    [No Abstract]   [Full Text] [Related]  

  • 2. [Polymorphisms of hormone-related genes and prostate cancer risk in Japan].
    Watanabe M; Hirokawa Y; Shiraishi T
    Nihon Rinsho; 2005 Feb; 63(2):219-24. PubMed ID: 15714969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular epidemiology of prostate cancer: androgens and polymorphisms in androgen-related genes.
    Ntais C; Polycarpou A; Tsatsoulis A
    Eur J Endocrinol; 2003 Dec; 149(6):469-77. PubMed ID: 14640986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics of human androgens and prostate cancer--an update.
    Novelli G; Margiotti K; Chiocca AM; Spera E; Micali F; Reichardt JK
    Pharmacogenomics; 2004 Apr; 5(3):283-94. PubMed ID: 15102543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer.
    Hofland J; van Weerden WM; Dits NF; Steenbergen J; van Leenders GJ; Jenster G; Schröder FH; de Jong FH
    Cancer Res; 2010 Feb; 70(3):1256-64. PubMed ID: 20086173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen metabolic genes in prostate cancer predisposition and progression.
    Makridakis NM; Buchanan G; Tilley W; Reichardt JK
    Front Biosci; 2005 Sep; 10():2892-903. PubMed ID: 15970543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk.
    Kakinuma H; Tsuchiya N; Habuchi T; Ohyama C; Matsuura S; Wang L; Nakamura A; Kato T
    Prostate Cancer Prostatic Dis; 2004; 7(4):333-7. PubMed ID: 15477877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular epidemiology and cancer prevention].
    Kamoto T; Ogawa O; Habuchi T; Kato T
    Hinyokika Kiyo; 2001 Nov; 47(11):833-6. PubMed ID: 11771181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility.
    Ross RK; Pike MC; Coetzee GA; Reichardt JK; Yu MC; Feigelson H; Stanczyk FZ; Kolonel LN; Henderson BE
    Cancer Res; 1998 Oct; 58(20):4497-504. PubMed ID: 9788589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic disorders of steroid hormone synthesis and metabolism.
    New MI; White PC
    Baillieres Clin Endocrinol Metab; 1995 Jul; 9(3):525-54. PubMed ID: 7575331
    [No Abstract]   [Full Text] [Related]  

  • 11. Molecular epidemiology of androgen-metabolic loci in prostate cancer: predisposition and progression.
    Makridakis NM; Reichardt JK
    J Urol; 2004 Feb; 171(2 Pt 2):S25-8; discussion S28-9. PubMed ID: 14713749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR.
    Cicek MS; Conti DV; Curran A; Neville PJ; Paris PL; Casey G; Witte JS
    Prostate; 2004 Apr; 59(1):69-76. PubMed ID: 14991867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inherited variation in hormone-regulating genes and prostate cancer survival.
    Lindström S; Adami HO; Bälter KA; Xu J; Zheng SL; Stattin P; Grönberg H; Wiklund F
    Clin Cancer Res; 2007 Sep; 13(17):5156-61. PubMed ID: 17785571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular action of androgen in the normal and neoplastic prostate.
    Kokontis JM; Liao S
    Vitam Horm; 1999; 55():219-307. PubMed ID: 9949683
    [No Abstract]   [Full Text] [Related]  

  • 15. Genetic polymorphisms and prostate cancer risk.
    Gsur A; Feik E; Madersbacher S
    World J Urol; 2004 Feb; 21(6):414-23. PubMed ID: 14648103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prospects of genetic polymorphism analyses in prostatic disease].
    Kagawa S; Nishitani MA
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():474-8. PubMed ID: 12599622
    [No Abstract]   [Full Text] [Related]  

  • 17. The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men.
    Allen NE; Forrest MS; Key TJ
    Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):185-9. PubMed ID: 11303586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steroid hormones and hormone-related genetic and lifestyle characteristics as risk factors for benign prostatic hyperplasia: review of epidemiologic literature.
    Neuhouser ML; Kristal AR; Penson DF
    Urology; 2004 Aug; 64(2):201-11. PubMed ID: 15302461
    [No Abstract]   [Full Text] [Related]  

  • 19. Androgen action: molecular mechanism and medical application.
    Liao S
    J Formos Med Assoc; 1994 Sep; 93(9):741-51. PubMed ID: 7735002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular mechanisms involved in hormone resistance of prostate cancer].
    Cabrespine A; Guy L; Chollet P; Debiton E; Bay JO
    Bull Cancer; 2004 Oct; 91(10):747-57. PubMed ID: 15556875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.